Japan Approves First RSV Vaccine Aimed at Adults 60 Years or Older
![](https://japannews.yomiuri.co.jp/wp-content/uploads/2023/02/health-ministry-1.jpg)
The Health, Labor and Welfare Ministry
15:35 JST, September 26, 2023
The Health, Labor and Welfare Ministry on Monday formally approved the respiratory syncytial virus vaccine developed by British pharmaceutical company GSK PLC. It is the first time Japan has approved an RSV vaccine for use in adults aged 60 or older.
The RS virus causes symptoms like those of the common cold but can lead to severe pneumonia for those with weakened immune systems, including infants and elderly people.
According to GSK, the vaccine lowered the risk of pneumonia and bronchitis by about 80% in adults aged 60 or older in its vaccine efficacy trials.
U.S. pharmaceutical company Pfizer Inc. has also applied for approval of its RSV vaccine.
"Science & Nature" POPULAR ARTICLE
-
Project to Mass Produce Japanese Glass Eels Succeeds in Reducing Costs; Pilot Scheme Brings Down Costs to ¥1,800 Per Fish
-
Namibia Fossil is ‘Swamp Thing’ with Menacing Fangs
-
Drones, Smartphones to Be Used to Assess Flood Damage; Cabinet Office Approves Tech to Speed up Disaster Certificate Issuance
-
3rd H3 Rocket Launched Successfully; Daichi-4 Satellite Shot into Orbit (UPDATE 2)
-
Japan to Promote Development of New Research Reactors to Achieve Decarbonization; Ministry Eyes Nuclear Power as ‘Leading Option’
JN ACCESS RANKING